Pharmaceutical Investing Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma
Pharmaceutical Investing FDA Determines that Afrezza REMS Communication Plan Has Met Goals and REMS No Longer Necessary
Pharmaceutical Investing Adamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI
BeiGene Presents Clinical Data on Pamiparib in Chinese Patients with Ovarian Cancers or Triple-Negative Breast Cancer
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas
Pharmaceutical Investing Idera Pharmaceuticals Enters into a Clinical Development Support Agreement with Pillar Partners Foundation to Expand the Clinical Research on IMO-2125
G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer
Pharmaceutical Investing Reata Provides Update on the Phase 2 Portion of the CARDINAL Study of Bardoxolone Methyl in Patients With Alport Syndrome
Pharmaceutical Investing Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Previously Treated Hepatocellular Carcinoma
Pharmaceutical Investing Data Monitoring Committee Completes Planned Safety and Data Review of Celsion’s Phase III OPTIMA Study
Pharmaceutical Investing Paratek’s New Drug Applications for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA
